June 12, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
CMS adopts performance-based standards for CRC biomarker tests; evidence questions linger
CMS established a new national framework setting performance thresholds to qualify noninvasive, biomarker-based colorectal cancer screening options — including FDA-approved stool- and blood-based tests — for coverage.“The CMS coverage decision provides benchmarks for novel noninvasive tests to meet and exceed to gain coverage, and learn from the experience of currently approved
709 words~3 min read
